Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ACAD ACADIA Pharmaceuticals Inc. daily Stock Chart
ACAD [NASD]
ACADIA Pharmaceuticals Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.97 Insider Own0.30% Shs Outstand144.31M Perf Week3.35%
Market Cap6.15B Forward P/E- EPS next Y-1.35 Insider Trans-12.83% Shs Float144.26M Perf Month43.87%
Income-267.90M PEG- EPS next Q-0.41 Inst Own98.50% Short Float8.93% Perf Quarter64.29%
Sales264.00M P/S23.29 EPS this Y-7.70% Inst Trans2.37% Short Ratio6.82 Perf Half Y58.25%
Book/sh2.69 P/B15.84 EPS next Y25.50% ROA-60.60% Target Price50.00 Perf Year206.92%
Cash/sh2.65 P/C16.10 EPS next 5Y26.50% ROE-71.00% 52W Range13.87 - 44.85 Perf YTD163.45%
Dividend- P/FCF- EPS past 5Y-34.30% ROI-51.90% 52W High-5.02% Beta2.87
Dividend %- Quick Ratio6.80 Sales past 5Y187.20% Gross Margin92.70% 52W Low207.14% ATR2.75
Employees477 Current Ratio6.80 Sales Q/Q45.70% Oper. Margin- RSI (14)71.52 Volatility7.18% 6.12%
OptionableYes Debt/Eq0.00 EPS Q/Q24.80% Profit Margin- Rel Volume1.77 Prev Close44.01
ShortableYes LT Debt/Eq0.00 EarningsJul 31 AMC Payout- Avg Volume1.89M Price42.60
Recom2.10 SMA2035.51% SMA5048.35% SMA20071.69% Volume3,334,906 Change-3.20%
Sep-13-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-10-19Upgrade Canaccord Genuity Hold → Buy $29 → $50
Jul-23-19Reiterated Needham Buy $40 → $34
Dec-10-18Initiated Canaccord Genuity Hold $23
Sep-21-18Upgrade Piper Jaffray Neutral → Overweight
Aug-09-18Reiterated Stifel Hold $17 → $14
Aug-07-18Initiated Stifel Hold $17
Aug-06-18Downgrade Piper Jaffray Overweight → Neutral
Oct-06-17Resumed Goldman Neutral
Nov-11-16Initiated Goldman Neutral
Nov-08-16Upgrade BofA/Merrill Neutral → Buy
Oct-19-16Resumed ROTH Capital Neutral
Oct-04-16Initiated Leerink Partners Mkt Perform $34
Jun-22-16Downgrade BofA/Merrill Buy → Neutral
May-03-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-30-16Reiterated Piper Jaffray Overweight $39 → $44
Feb-08-16Initiated BofA/Merrill Buy $40
Jan-22-16Upgrade Piper Jaffray Neutral → Overweight
Aug-27-15Upgrade Piper Jaffray Neutral → Overweight $48
Aug-07-15Reiterated Needham Buy $38 → $49
Sep-17-19 04:02PM  ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
Sep-11-19 10:23AM  3 Hot Biotechs with High Upside Potential TipRanks
Sep-10-19 01:20PM  'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis Benzinga +6.10%
11:41AM  ACADIA Surges on Early Success of Nuplazid Dementia Study Zacks
10:59AM  Will ACADIA Continue to Surge Higher? Zacks
08:39AM  Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now? Motley Fool
07:36AM  The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris Benzinga
Sep-09-19 05:38PM  Why Acadia Pharmaceuticals Stock Skyrocketed Today Motley Fool +63.24%
04:55PM  ACADIA Pharmaceuticals Help Lift Biotech ETFs ETF Trends
04:26PM  Why This Biotech Stock Just Rocketed 63% After Hitting A 4-Year High Investor's Business Daily
04:13PM  What Happened in the Stock Market Today Motley Fool
02:33PM  Acadia Stops Nuplazid Study Early After Drug Shows 'Statistically Superior Efficacy' In Dementia-Related Psychosis Benzinga
12:17PM  A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019 Benzinga
10:26AM  Options Hot as ACADIA Pharmaceuticals Stock Soars Schaeffer's Investment Research
09:05AM  ACADIA Enters Oversold Territory Zacks
07:31AM  [video]Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment TheStreet.com
07:26AM  Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint MarketWatch
06:30AM  ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis Business Wire
Sep-04-19 09:00AM  ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019 Business Wire
Aug-29-19 12:47PM  Top Ranked Momentum Stocks to Buy for August 29th Zacks
Aug-27-19 10:29AM  Is There An Opportunity With ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) 37% Undervaluation? Simply Wall St.
Aug-26-19 08:39AM  Top Ranked Momentum Stocks to Buy for August 26th Zacks
Aug-23-19 11:44AM  Top Ranked Momentum Stocks to Buy for August 23rd Zacks
Aug-20-19 08:34AM  Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment Zacks
Aug-16-19 10:42AM  Palatin's (PTN) to Report Q4 Earnings: What's in the Cards? Zacks
Aug-15-19 09:43AM  Top Ranked Momentum Stocks to Buy for August 15th Zacks
Aug-14-19 11:09AM  Top Ranked Momentum Stocks to Buy for August 14th Zacks
Aug-12-19 09:09AM  Top Ranked Momentum Stocks to Buy for August 12th Zacks
Aug-06-19 08:08AM  ACADIA Pharmaceuticals Inc. (ACAD) Shares March Higher, Can It Continue? Zacks
Aug-02-19 11:28AM  Edited Transcript of ACAD earnings conference call or presentation 31-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-01-19 12:06PM  Why Acadia Pharmaceuticals Stock Is Crushing It Today Motley Fool +16.64%
06:00AM  Acadia Pharmaceuticals Beats Expectations in Q2 Motley Fool
02:24AM  Acadia Pharmaceuticals (ACAD) Q2 2019 Earnings Call Transcript Motley Fool
Jul-31-19 06:55PM  Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results Business Wire
02:30PM  ACADIA Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
07:06AM  The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster Benzinga
Jul-24-19 10:32AM  Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-23-19 11:38AM  Why Acadia Pharmaceuticals Is Tanking Today Motley Fool -14.44%
11:00AM  Are These 2 Beaten-Down Biotech Stocks Worth Buying? Motley Fool
07:26AM  The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation Benzinga
Jul-22-19 04:53PM  Acadia stock drops as schizophrenia drug doesn't pass clinical trial MarketWatch
04:44PM  Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16% Reuters
04:14PM  Acadia's schizophrenia treatment fails to meet main goal of late-stage study Reuters
04:05PM  ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia Business Wire
01:56PM  Acadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails Study TheStreet.com
Jul-17-19 09:00AM  ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019 Business Wire
Jul-11-19 06:36AM  Does ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Salary Reflect Performance? Simply Wall St.
Jun-25-19 08:50AM  New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners PR Newswire
Jun-11-19 08:23PM  Is ACADIA Pharmaceuticals Inc. (ACAD) A Good Stock To Buy? Insider Monkey
06:59AM  When Will ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Turn A Profit? Simply Wall St.
Jun-04-19 09:00AM  ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference Business Wire
May-18-19 11:00AM  ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting Business Wire
May-09-19 03:57AM  Edited Transcript of ACAD earnings conference call or presentation 1-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-08-19 03:30PM  Why Acadia Pharmaceuticals Stock Slumped in April Motley Fool
May-07-19 09:00AM  ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019 Business Wire
May-02-19 03:24AM  Acadia Pharmaceuticals (ACAD) Q1 2019 Earnings Call Transcript Motley Fool +7.78%
May-01-19 07:35PM  Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Tops Revenue Estimates Zacks
06:29PM  Acadia: 1Q Earnings Snapshot Associated Press
04:05PM  ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results Business Wire
Apr-29-19 09:58PM  Were Hedge Funds Right About Flocking Into ACADIA Pharmaceuticals Inc. (ACAD)? Insider Monkey
Apr-26-19 06:10AM  Analysts point to potential Biogen M&A options after Alzheimer's failure American City Business Journals
Apr-25-19 09:00AM  ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder Business Wire
Apr-24-19 10:33AM  Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-19-19 09:11AM  Should ACADIA Pharmaceuticals (NASDAQ:ACAD) Be Disappointed With Their -30% Profit? Simply Wall St.
Apr-17-19 09:00AM  ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019 Business Wire -8.58%
Apr-11-19 09:00AM  ACADIA Pharmaceuticals Supports Parkinsons Disease Awareness Month and World Parkinsons Day with Local Educational Initiatives and Community Events Across the Country Business Wire
Apr-02-19 09:00AM  ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019 Business Wire
Apr-01-19 09:00AM  ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer Business Wire
Mar-29-19 07:20AM  Analysis: Positioning to Benefit within American Water Works, TripAdvisor, ACADIA Pharmaceuticals, Dril-Quip, Domtar, and Cara Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-28-19 12:14PM  U.S. Stocks Are Still Stuck Because Uncertainty Is Everywhere Barrons.com
07:54AM  The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO Benzinga
Mar-27-19 04:10PM  Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology Business Wire
Mar-21-19 06:30AM  HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results CNW Group
Mar-13-19 01:18PM  Is ACADIA Pharmaceuticals Inc.s (NASDAQ:ACAD) Liquidity Good Enough? Simply Wall St.
Mar-05-19 10:40PM  Edited Transcript of ACAD earnings conference call or presentation 26-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
02:36PM  Why Acadia Pharmaceuticals Stock Perked Up in February Motley Fool
Mar-04-19 09:00AM  ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019 Business Wire
Feb-27-19 09:30AM  3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks TheStreet.com +8.36%
01:05AM  Acadia Pharmaceuticals Inc (ACAD) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-26-19 04:05PM  ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
01:28PM  Big Pharma faces the Senate in drug price hearings Yahoo Finance Video
Feb-21-19 09:00AM  ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019 Business Wire
Feb-15-19 04:08PM  What's in the Cards for Bausch Health (BHC) Q4 Earnings? Zacks +6.02%
Feb-14-19 12:58PM  5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings Zacks
Feb-13-19 08:15AM  New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-12-19 09:00AM  ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019 Business Wire
Feb-11-19 04:51PM  Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards? Zacks
03:58PM  Is a Disappointment in Store for Incyte (INCY) Q4 Earnings? Zacks
Feb-08-19 04:56PM  Tilray (TLRY) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-07-19 04:31PM  Exelixis (EXEL) to Report Q4 Earnings: What's in Store? Zacks
Jan-31-19 07:18PM  Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales? Zacks
Jan-30-19 10:02AM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
Jan-28-19 09:37AM  MacroGenics Up on Lifting of Partial Hold on Cancer Candidate Zacks
08:00AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and ACADIA Pharmaceuticals ACCESSWIRE
Jan-24-19 06:46AM  Will ACADIA Pharmaceuticals Continue to Surge Higher? Zacks
Jan-21-19 11:48AM  Does ACADIA Pharmaceuticals Inc.s (NASDAQ:ACAD) CEO Pay Compare Well With Peers? Simply Wall St.
Jan-17-19 10:18AM  Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod Zacks
Jan-11-19 06:08PM  Glancy Prongay & Murray LLP Announces Investigation On Behalf Of ACADIA Pharmaceuticals Inc. Investors (ACAD) GlobeNewswire
Jan-10-19 07:00AM  Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and ACADIA Pharmaceuticals ACCESSWIRE
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Miller Eric AlejandroController & PAOSep 11Sale41.184,645191,2810Sep 11 07:19 PM
Daly James MDirectorSep 09Option Exercise17.5230,000525,60030,000Sep 11 07:18 PM
Miller Eric AlejandroController & PAOSep 09Option Exercise28.7128,467817,21833,112Sep 11 07:19 PM
Miller Eric AlejandroController & PAOSep 09Sale39.4928,4671,124,1624,645Sep 11 07:19 PM
Daly James MDirectorSep 09Sale37.8030,0001,133,8600Sep 11 07:18 PM
Brege LauraDirectorJan 09Option Exercise2.1610,00021,60010,000Jan 11 04:32 PM
Brege LauraDirectorJan 09Sale20.0010,000200,0410Jan 11 04:32 PM
BAKER BROS. ADVISORS LPDirectorNov 30Buy17.0011,764,705199,999,98535,976,940Dec 04 05:00 PM
BAKER BROS. ADVISORS LPDirectorSep 20Buy18.701,210,77622,646,98924,798,117Sep 24 08:32 AM
open in yahoo | open in reuters | open in google